Table 1 Demographic and clinical characteristics of the Aim 1 & 2 samples.
Aim 1 samples | Aim 2 sample | ||
|---|---|---|---|
LPP gain | LPP loss | Alpha ERD | |
n | 166 | 168 | 84 |
Age (in years), M ± SD (Visit 1, baseline) | 15.75 ± 1.07 | 15.77 ± 1.06 | 15.76 ± 1.05 |
Age (in years), M ± SD (Visit 2, baseline) | 15.83 ± 1.08 | 15.83 ± 1.07 | 15.83 ± 1.06 |
Age (in years), M ± SD (Visit 1, follow-up) | 17.25 ± 1.07 | 17.26 ± 1.06 | 17.24 ± 1.06 |
Age (in years), M ± SD (Visit 2, follow-up) | 17.33 ± 1.06 | 17.33 ± 1.06 | 17.30 ± 1.05 |
Sex | 71 female / 95 male | 72 female / 96 male | 35 female / 49 male |
IQ percentile, M ± SD | 62.83 ± 20.48 | 62.73 ± 20.5 | 64.57 ± 21.33 |
Net household income per person (in HUF)†, M ± SD | 172363.9 ± 89332.23 | 171516.3 ± 89205.67 | 167763.3 ± 77013.34 |
With ADHD# | 39 (23.49%) | 39 (23.21%) | 27 (32.14%) |
Medication-naїve at baseline& | 21 (53.85%) | 21 (53.85%) | 16 (59.26%) |
On stimulant medication at baseline& | 6 (15.38%) | 6 (15.38%) | 2 (7.41%) |
On nonstimulant medication at baseline& | 3 (7.69%) | 3 (7.69%) | 2 (7.41%) |
Took ≥24-hour medication hiatus before baseline EEG^ | 18 yes / 2 no / 7 did not indicate | 18 yes / 2 no / 7 did not indicate | 13 yes / 1 no / 4 did not indicate |
Medication-naїve at follow-up& | 17 (43.59%) | 17 (43.59%) | 12 (44.44%) |
On stimulant medication at follow-up& | 1 (2.56%) | 1 (2.56%) | 0 (0%) |
On nonstimulant medication at follow-up& | 9 (23.08%) | 9 (23.08%) | 6 (22.22%) |
Took ≥24-hour medication hiatus before follow-up EEG^ | 15 yes / 2 no / 7 did not indicate | 15 yes / 2 no / 7 did not indicate | 10 yes / 1 no / 4 did not indicate |
